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Abstract 
Purpose: This meta-analysis aimed to systematically evaluate the efficacy of tyrosine kinase inhibitors 
of epidermal growth factor receptor (EGFR-TKIs) for patients with brain metastases (BM) from non-
small-cell lung cancer (NSCLC), and to compare this treatment modality to chemotherapy or 
radiotherapy. 
Methods: PubMed, EMBASE (OvidSP), the Cochrane Central Register of Controlled Trials 
(CENTRAL), Web of Science and ASCO Annual Meeting Abstracts were searched. Controlled clinical 
studies that compared the efficacy of EGFR-TKIs with chemotherapy or radiotherapy for NSCLC 
patients with BM were included in the analysis. Efficacy indicators included overall survival (OS), local 
progression-free survival (LPFS) and objective response rate (ORR).  
Results: The final sample consisted of 24,637 NSCLC patients with BM from 11 clinical studies. In 
primary efficacy analysis, it was found that EGFR-TKIs were significantly superior to chemotherapy or 
radiotherapy in terms of ORR (odds ratio (OR) = 2.10, p = 0.035), OS (hazard ratio (HR) = 0.78, p = 
0.011) and LPFS (HR = 0.60, p < 0.001).  
Conclusion: Among the patients with BM from NSCLC, EGFR-TKIs exhibit a therapeutic advantage 
over chemotherapy or radiotherapy, which is reflected in the elevation of ORR and improvement in OS 
and LPFS.  
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Lung cancer is the most common cancer and is 
the major cause of cancer-related deaths, 
accounting for 13.0 % of new cancer cases and 
19.4 % of cancer-related deaths in men and 
women according to the 2012 statistics [1]. About 
85 % of the lung cancer cases are classified as 
NSCLC [2], which has a relatively high risk of 
BM, ranging from 20 to 40 % [3,4]. The prognosis 
of NSCLC patients with BM is very 
unsatisfactory, with median OS time being < 3 
months if untreated [5]. 
 
The therapies for NSCLC patients with BM 
include surgery, stereotactic radiosurgery (SRS), 
chemotherapy, whole brain radiation therapy 
(WBRT), EGFR-TKIs or any combinations 
thereof. However, chemotherapy is not a routine 
treatment because of the inability of many 
systemically active chemotherapeutic drugs to 
cross the blood–brain barrier (BBB). Surgery and 
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SRS are not ideal options for NSCLC patients 
with BM considering the poor outcome. WBRT 
has been regarded as the standard treatment 
plan for multiple BM; it can stabilize or shrink 
tumors in at least half of the patients, but many 
patients experience tumor recurrence either at 
the original sites or at new sites [6].  
 
As micro-molecularly-targeted drugs, EGFR-
TKIs, such as gefitinib or erlotinib, can penetrate 
the BBB in a certain proportion [7,8]. This is an 
important characteristic to consider when the 
treatment options of patients with BM from 
NSCLC are evaluated. In addition, EGFR-TKIs 
are believed to possess the ability to reinforce 
radioactive sensitivity through multiple means 
[9,10]. 
 
Many studies have shown the responses of 
NSCLC patients with BM to EGFR-TKIs [11-14], 
but most of the studies involved small sample 
sizes, contained only case reports, or were 
single-arm. Moreover, negative conclusions were 
reached based on the findings from some 
studies. For example, OS, PFS and toxicity in the 
WBRT + SRS + erlotinib group were completely 
less satisfactory when compared to those of the 
WBRT + SRS group in a phase III clinical trial. 
Three meta-analyses on the benefit of EGFR-
TKIs among patients with BM from NSCLC have 
also been published, but only one included 16 
single-arm studies [15]  and the other two [16,17] 
respectively evaluated the efficacy and safety of 
TKIs and radiotherapy in relatively few 
participants. 
 
In 2015, Lin [18] found extended period of 
survival in NSCLC patients with BM who were 
receiving gefitinib or gamma knife radiosurgery 
by analyzing medical records of 23,874 target 
patients based on the National Health Insurance 
Research Database of Taiwan from 2004 to 
2010. Results from such large sample size 
studies provide more dependable data. 
Therefore, in the present study, we performed 
this meta-analysis to systematically examine the 
efficacy of EGFR-TKIs for NSCLC patients with 
BM, and the outcome of this treatment modality 
was compared with those of chemotherapy and 
radiotherapy. This pooled evaluation, based on 
controlled studies can assist doctors to make 
better clinical decisions for the treatment of 






Our meta-analysis was based on the preferred 
reporting items for systematic reviews and meta-
analyses (PRISMA) Statement, in which 
PubMed, EMBASE (OvidSP), the Cochrane 
Central Register of Controlled Trials (CENTRAL, 
last issue), Web of Science and ASCO (The 
American Society of Clinical Oncology) annual 
meeting abstracts which were painstakingly 
searched for the presence of relevant papers that 
were published from January 2000 until 
December 2016. The keywords were as follows: 
non-small cell lung cancer OR non-small cell 
lung carcinoma OR NSCLC OR large cell lung 
cancer OR lung adenocarcinoma OR lung 
squamous cell carcinoma OR lung squamous 
carcinoma; epidermal growth factor receptor OR 
EGFR OR erbB-1 OR erlotinib OR gefitinib OR 
Tarceva OR Iressa OR ZD1839 OR icotinib OR 
afatinib OR Gilotrif; and brain metastasis OR 
central nervous system metastasis OR CNS 
metastasis OR cerebral metastasis. The subject 
heading search was also performed in specific 
databases. Moreover, other conference papers 
and the reference lists of selected studies were 
searched for manually. The search for 
publications was not restricted to type of 





Two of the authors (ZW and HLJ) reviewed the 
titles and abstracts of all papers identified from 
electronic sources and those from manual 
retrieval, respectively. Only studies that met the 
following eligibility criteria were included for the 
purpose of quantitative synthesis: (a) controlled 
clinical studies (even retrospective clinical 
designs in consideration of the small number of 
eligible publications) in which the experimental 
group received EGFR-TKIs alone or a 
combination of EGFR-TKIs with chemotherapy or 
radiotherapy and in which the control group 
received only chemotherapy, radiotherapy or a 
combination of chemotherapy and radiotherapy; 
(b) the patients in the studies or in the subgroup 
analyzed and confirmed to have NSCLC with 
brain metastasis; (c) original papers that 
contained adequate data to estimate the 
indicators of efficacy with a 95 % confidence 
interval (95 %CI). Repeated publication and non-
original literature (e.g., comment, letter, review, 
etc.) were excluded. If no agreement could be 
reached after a discussion between the two 
reviewers in terms of study selection, a third 




The ORR was defined as the percentage of 
complete response and partial response among 
the evaluated patients. OS referred to the time 
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from randomization to death regardless of the 
cause of death. LPFS was thought as the length 
of time from randomization to central nervous 
system, neurological or intracranial progression 
or death. In this meta-analysis, the odds ratio 
(OR) for the ORR and the hazard ratios (HRs) for 
OS and LPFS were primary indicators for the 
assessment of the efficacy of EGFR-TKIs for 
NSCLC patients with BM. 
 
Data extraction and quality assessment 
 
In the meta-analysis, the following information 
was collected independently by two authors (ZW 
and HLJ) from each study: first author, 
publication year, country of study, study design, 
treatments in the different groups, number of 
patients, endpoint types, patient characteristics 
(age, gender, stage, response status, EGFR 
mutation status) and outcome measures 
(response rate, median OS and LPFS, HRs for 
OS and LPFS and their 95 % CIs). Results that 
were obtained by multivariate analysis were 
preferred. If the HRs for OS or LPFS were not 
provided in the papers, log-transformed HRs and 
variance were estimated from Kaplan-Meier 
curves with the Engauge graphic software 
package [19]. Moreover, the risks of bias of the 
included studies were evaluated independently 
by two authors (ZW and HLJ) on the basis of The 
Cochrane Handbook for Systematic Reviews 
(version 5.1.0). HCH was still the final decision-
maker when no consensus could be reached 
between the other two reviewers.  
 
This research was approved by the Ethical 
Committee of Department of Biostatistics, School 
of Public Health, Fudan University, Shanghai, 
China according to the Declaration of Helsinki 




The analysis was based on the intention-to-treat 
(ITT) principle. Potential heterogeneity was first 
detected among the studies using Cochran's Q-
statistic and I2 score [21], which is thought as 
statistically significant if the p-value for 
heterogeneity is less than 0.10 or if I2 is greater 
than 50 %. If heterogeneity was found, the 
random-effects model [22] was applied to pool all 
effect measures including odds ratio for the 
objective response rate and HRs for OS and 
LPFS; otherwise, the fixed-effects model (inverse 
variance method) [23] was used. To assess the 
presence of possible publication bias, Egger’s 
regression asymmetry test with a funnel plot was 
performed [24]. Its significant level was 0.10. The 
sensitivity analysis was performed to examine 
the influence of the study design, study quality 
and treatment plan on the evaluation of the 
study’s efficacy. 
 
The statistical software package used was 
STATA 11.2 (Stata Corporation, College Station, 
TX, USA). All p-values were two-sided. For the 
examination of the pooled effect indicators, p < 




Characteristics of studies 
 
From the 266 studies that were screened, 216 
articles were excluded because of apparent non-
conformity with the eligibility criteria, and 50 full-
text papers were accessed to further evaluate 
their eligibility. Next, 15 studies were enrolled in 
the qualitative synthesis, and 11 studies (see 18, 
25 – 34, Table 1) that met all criteria were finally 
selected for the quantitative synthesis. A 
flowchart of the selection process is presented in 
Figure 1. The 11 eligible studies included 2 
phase III trials, 3 phase II trials, 1 undefined 
phase trial and 5 retrospective clinical studies. 
The final sample consisted of 24,637 patients 
with BM from NSCLC, which included 3,773 in 
the EGFR-TKIs arm and 20,864 in the control 
group. Five of the 11 studies were from the 
Chinese mainland, 2 from Taiwan, 1 from 
Germany, 1 from the United Kingdom, 1 from the 
United States and 1 from Switzerland. All 
subjects in study 1(one) were EGFR-mutant, and 
2 studies provided the subgroup analysis for 
EGFR-mutant and EGFR wild-type patients, but 
the mutation status for the rest of the patients 
could not be verified or analyzed. Of the 11 
eligible studies, 3 featured EGFR-TKI 
combination therapy compared with combined 
radiotherapy or chemotherapy, 5 featured EGFR-
TKI combination therapy compared with 
radiotherapy alone, and 3 featured EGFR-TKI 
alone compared with chemotherapy or 
radiotherapy alone. All studies included were 
peer-reviewed. The characteristics of the 
included studies are summarized in Table 1. 
 
Primary efficacy analysis 
 
Among the 11 included studies, 6 reported 
objective response rates (numbers 26-28; 20-32; 
Table 1), and a statistically significant 
heterogeneity was detected across the studies (I2 
= 91.1 %, p < 0.001). The pooled OR for the 
ORR obtained by a random effects model was 
2.10 (95 % CI: 1.05 – 4.20, p = 0.035, Figure 2). 
From these data, EGFR-TKIs were significantly 
better than chemotherapy or radiotherapy. 
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Table 1: Characteristics of the studies included in the meta-analysis 
 
Author Year Country Type of study EGFR mutation (+) Treatment N ORR (%) OS (months) LPFS (months) Quality 
Lin, C[18] 2015 TW retrospective Portion of patients GFT + WBRT 3379 NA 6.4 NA B 
     WBRT 20241 NA 12.1 NA  
Sperduto, PW [25]  2013 USA phase III Unselected ETN+WBRT + SRS 41 NA 6.1 4.8 B 
     WBRT + SRS 44 NA 13.4 8.1  
Schuler, M[26]  2016 GER phase III All patients Afatinib 48 75.0 22.4 8.2 A 
     Pemetrexed/ Cisplatin 33 27.8 25.0 5.4  
Cai, Y[27] 2013 PRC retrospective Portion of patients (GFT or ETN)+WBRT 65 76.9 10.6 6 B 
     WBRT 92 70.7 7.7 3.4  
Fu, H[28] 2012 PRC retrospective Unselected GFT + (WBRT or SRS)  38 31.6 NA NA C 
     WBRT or SRS 123 15.4 NA NA  
Lee, SM [29] 2014 UK phase II Portion of patients  ETN+WBRT 40 NA 3.4 1.6 B 
     Placebo +WBRT 40 NA 2.9 1.6  
Wang, F[30] 2014 PRC undefined phase Portion of patients GFT + RT 37 54.1 13.3 NA B 
     VMP+RT 36 47.1 12.7 NA  
 
Table 1(b): Characteristics of the studies included in the meta-analysis 
Author Year Country Type of study EGFR mutation (+) Treatment N ORR (%) OS (months) LPFS (months) Quality 
Zhuang, HQ[31] 2013 PRC phase II Portion of patients ETN+WBRT 23 95.7 10.7 6.8 B 
     WBRT 31 54.8 8.9 5.2  
Hsiao, SH[32] 2013 TW retrospective Portion of patients EGFR TKIs  11 55 9.8 NA B 
     RT 70 76 10.6 NA  
Fan, Y[33] 2013 PRC retrospective Portion of patients EGFR TKIs 75 NA 12 NA B 
     Chemotherapy 111 NA 9 NA  
Pesce, GA[34] 2011 CH phase II Unselected GFT + RT 16 NA 6.3 4.8 B 
     TMZ + RT 43 NA 4.9 8.0  
Key: NA: not available WBRT: whole brain radiotherapy SRS: stereotactic radiosurgery ETN: Erlotinib GFT: Gefitinib TMZ: Temozolomide RT: Radiotherapy 
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    Figure 1: PRISMA flow diagram of the identification process 
 
NOTE: Weights are from random effects analysis





























Figure 2: Forest plot of odds ratios for the objective response rate according to primary efficacy analysis 
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Data on the OS were available in 10 studies 
[18,26-34], and the pooled HR for the OS was 
0.78 (95 % CI: 0.65 - 0.94, p = 0.011, Figure 3), 
which presented a significant difference between 
EGFR-TKIs and chemotherapy or radiotherapy. 
A random effects model was also used on 
account of significant heterogeneity (I2 = 70.8 %, 
p < 0.001). 
 
The HRs for the LPFS with a 95 % CI were 
provided in 4 studies [26,27,29,31], and the 
pooled HR between EGFR-TKIs and 
chemotherapy or radiotherapy was regarded as 
significantly different (HR = 0.60, 95 % CI: 0.47 – 
0.78, p < 0.001, Figure 4) using a fixed effects 
model (I2 = 44.8 %, p = 0.143). These results 




One sensitivity analysis was performed by the 
inclusion of only 6 randomized controlled trials 
(RCTs) [25,26,29-31,34]. The LPFS in the 
EGFR-TKIs treatment group was significantly 
better than that in the control group (HR: 0.63, 95 
% CI: 0.44 – 0.89, p = 0.009, Figure 5), but 
negative results were found in terms of the ORR 
and the OS (OR for ORR: 4.81, 95 % CI: 0.98 – 
23.69, p = 0.054; HR for OS: 0.97, 95 % CI: 0.77 
– 1.21, p = 0.768, Figure 5). 
 
In another sensitivity analysis, only 8 studies that 
featured the treatment group that received 
radiotherapy combined with EGFR-TKIs were 
included [18,25,27-31,34]. All the efficacy 
indicators showed a significant improvement 
among patients in the EGFR-TKI plus concurrent 
radiotherapy group when compared with patients 
who received radiotherapy alone, chemotherapy 
alone or a combination of radiotherapy and 
chemotherapy (OR for ORR: 1.82, 95 % CI: 1.14 
– 2.92, p = 0.012; HR for OS: 0.78, 95 % CI: 0.64 
– 0.97, p = 0.024; HR for LPFS: 0.59, 95 % CI: 




The result of Egger’s asymmetry test did not 
show any evidence of publication bias (p = 0.683 





The meta-analysis carried out in the present 
study included 24,637 NSCLC patients with BM 
from 6 randomized controlled trials and 5 
retrospective clinical studies. The vast majority of 
the patients came from East Asia, including the 
Chinese mainland and Taiwan. This meta-
analysis was aimed at assessing the value of 
EGFR-TKIs therapy in NSCLC patients with 
BMs. 
NOTE: Weights are from random effects analysis









































Figure 3: Forest Plot of the hazard ratio for the overall survival according to primary efficacy analysis 
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NOTE: Weights are from random effects analysis























         Figure 4: Forest Plot of the hazard ratio for the LPFS according to primary efficacy analysis 
 
 
Figure 5: Forest Plot of the efficacy indicators in the sensitivity analysis that only included randomized controlled 
trials. Pooled result of the ORR was from a random effects analysis, while the OS and the PFS were from a fixed 
effects analysis 
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Figure 6: Forest Plot of efficacy indicators in the sensitivity analysis that only included the studies with combined 
radiotherapy in the EGFR-TKI treatment group. Pooled results of the ORR and the OS were from a random 
effects analysis, while the PFS was from a fixed effects analysis. 
 
The results indicated that EGFR-TKIs were 
significantly superior to chemotherapy or 
radiotherapy in terms of ORR (OR = 2.10, p = 
0.035), OS (HR = 0.78, p = 0.011) and LPFS (HR 
= 0.60, p < 0.001). The data suggested that 
EGFR-TKIs therapy for advanced NSCLC 
patients with BM not only could improve the 
short-term quality of life, but also could prolong 
the overall lifespan. 
 
Systemic chemotherapy for central nervous 
system (CNS) metastases has only played a 
limited role in the treatment of patients with BM 
from NSCLC because of the existence of the 
blood–brain barrier (BBB). However, as a micro-
molecule and highly permeable compound, an 
EGFR-TKI can pass through the BBB in a certain 
proportion and target intracranial lesions. A 
pharmacokinetic study indicated that the 
penetration rates of erlotinib and gefitinib in the 
cerebrospinal fluid (CSF) were 2.77 ± 0.45 % 
and 1.13 ± 0.36 %, respectively [35]. In clinical 
practice, EGFR-TKIs were thought to be an 
important treatment option for these patients. 
The present meta-analysis strengthened the 
evaluation of the therapeutic efficacy of EGFR-
TKIs in a target population by pooling all the 
existing controlled studies, in which three primary 
measures favored EGFR-TKI therapy. 
 
WBRT is considered as the standard treatment 
plan for multiple brain metastases because 
radiation not only kills the tumor cells, but also 
damages endothelial cells of the BBB and thus 
increases its permeability. This characteristic can 
increase the concentration of EGFR-TKIs in the 
brain without a dose escalation and it also allows 
for the combination of EGFR-TKI therapy and 
WBRT [36]. In addition, EGFR-TKIs are able to 
sensitize tumor cells to radiation and improve 
local control rates. Thus, the combination of 
EGFR-TKIs with concurrent radiotherapy seems 
to have a strong theoretical basis for the 
production of a synergistic action that enhances 
the therapeutic efficacy and reduces the side 
effects of each therapy. In a phase II trial of 
erlotinib with concurrent WBRT for patients with 
BM from NSCLC that was published in Journal of 
Clinical Oncology in 2013 [37], the ORR was 86 
%, and the median OS was 11.8 months (95 % 
CI: 7.4 – 19.1 months). 
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          Figure 7: Egger’s publication bias plot 
 
Meanwhile, no increase in neurotoxicity, or any 
grade >/= 4 toxicity, was detected. A meta-
analysis [16] also suggested, by evaluating the 
therapeutic effects among 980 NSCLC patients 
with BM, that EGFR-TKIs combined with 
radiotherapy produced superior efficacy and 
safety. The efficacy of combination therapy was 
similarly confirmed by a sensitivity analysis in this 
study, which was performed by the inclusion of 
24,289 participants from the studies with groups 
that received a combination of radiotherapy and 
EGFR-TKIs. In this analysis, the ORR, OS and 
LPFS of patients who received concurrent 
EGFR-TKIs and radiotherapy were significantly 
superior to the same indicators of patients who 
received radiotherapy alone, chemotherapy 
alone or a combination of chemotherapy and 
radiotherapy (OR for ORR: 1.82, p = 0.012; HR 
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for OS: 0.78, p = 0.024; HR for LPFS: 0.59, p = 
0.036). 
 
Another sensitivity analysis was performed to 
explore the efficacy of EGFR-TKIs in current 
clinical trials with randomization and comparison. 
The difference in the LPFS was still statistically 
significant (HR: 0.63, p = 0.009), which 
demonstrated that EGFR-TKIs could more 
effectively control local progression of cancer. 
Although the ORR did not favor EGFR-TKIs (OR: 
4.81, p = 0.054), the ORRs in the EGFR-TKIs 
treatment group were clearly higher than those in 
the control group in all three clinical trials that 
reported the ORR (72.9 vs 24.2 %, 54.1 vs 47.1 
%, 95.7 vs 54.8 %). Therefore, the negative 
result in the ORR possibly originates from a lack 
of robustness in a few studies and the choice of 
random effects model due to high heterogeneity. 
The prolonged LPFS benefit did not translate into 
a benefit in the OS (HR: 0.97, p = 0.768), and 
further well-designed RCT(s) with larger sample 
sizes are needed to investigate the effect of 
EGFR-TKIs in terms of an overall survival 
advantage.  
 
Thus far, EGFR mutation status has been 
thought to be strongly associated with the 
response to EGFR-TKI therapy in patients with 
extra-cranial NSCLC [38,39], but this correlation 
in patients with BM requires close scrutiny 
because the mutation status of primary and 
metastatic lesions may be different. The authors 
of a recent meta-analysis [15] observed 
therapeutic effects with an ORR of 85.0 vs 45.1 
% and a disease control rate of 94.6 vs 71.3 % 
for the EGFR mutation and unselected groups, 
respectively. In addition, individuals with EGFR 
mutations also demonstrated a therapeutic 
advantage in terms of median PFS and OS. This 
pooled analysis was based entirely on single-arm 
studies, and thus due to a lack of comparison, it 
could not be evaluated for statistical significance. 
In our meta-analysis, the pooled efficacy 
indicators in the subgroup with or without EGFR 
mutations could not be provided owing to the 
limited number of studies. However, the results 
of the evaluations of the efficacy of EGFR-TKI 
therapy were contradictory in only 2 subgroup 
analyses of 11 eligible studies [31,33]. Additional 
work is still required to clarify the impact of EGFR 
mutation status on the therapeutic benefit of 
EGFR-TKIs among patients with BM from 
NSCLC. 
 
Some limitations were encountered and noted in 
the present pooled analysis. First, our meta-
analysis was based on published studies; hence, 
any potential publication bias could not be 
eliminated. Second, we included five 
retrospective studies, which might have led to 
additional bias from the lack of randomization 
and the reference to historical data. Although a 
sensitivity analysis was performed by the 
inclusion of only 5 RCTs to control for the bias, a 
reduced study number may have restricted the 
reliability of the analysis. Third, the therapeutic 
effects of different EGFR-TKI agents could not 
be distinguished and compared on account of the 
number and background of the enrolled studies; 
nevertheless, it was recognized that the 
advantages of gefitinib, erlotinib and the new 
generation of EGFR-TKIs were different. Finally, 
high heterogeneity existed when we conducted 
the analysis of the ORR and OS. If possible, 





It is evident from the present pooled analysis that 
EGFR-TKIs has a therapeutic advantage over 
chemotherapy or radiotherapy for patients with 
BM from NSCLC; this conclusion is based on the 
elevation of the ORR and the improvement in OS 
and LPFS. Furthermore, large RCTs are required 
in order to determine the efficacy benefit and the 
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